Unnamed: 0,title,date,stock,sentiment
1030460.0,"UBS Maintains Neutral on PRA Health Sciences, Lowers Price Target to $101",2020-05-05 10:38:00-04:00,PRAH,negative
1030461.0,"Baird Maintains Outperform on PRA Health Sciences, Lowers Price Target to $101",2020-05-04 08:35:00-04:00,PRAH,negative
1030462.0,"Credit Suisse Maintains Outperform on PRA Health Sciences, Lowers Price Target to $113",2020-05-01 08:40:00-04:00,PRAH,positive
1030463.0,William Blair Downgrades PRA Health Sciences to Market Perform,2020-05-01 05:58:00-04:00,PRAH,neutral
1030464.0,"PRA Health Sciences Sees Q2 Sales $705M-$740M Vs. $684.43M	Est., EPS $0.75-$0.90 Vs. $0.95 Est.",2020-04-30 16:10:00-04:00,PRAH,neutral
1030465.0,PRA Health Sciences Withdraws Full-Year FY20 Guidance,2020-04-30 16:09:00-04:00,PRAH,neutral
1030466.0,"PRA Health Sciences Q1 EPS $1.050 Beats $1.020 Estimate, Sales $783.708M Beat $757.010M Estimate",2020-04-30 16:09:00-04:00,PRAH,neutral
1030467.0,"The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1",2020-04-30 07:19:00-04:00,PRAH,positive
1030468.0,"UBS Maintains Neutral on PRA Health Sciences, Lowers Price Target to $103",2020-04-28 11:45:00-04:00,PRAH,negative
1030469.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,PRAH,negative
1030470.0,"Barclays Maintains Overweight on PRA Health Sciences, Lowers Price Target to $114",2020-03-26 11:05:00-04:00,PRAH,negative
1030471.0,"The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test",2020-03-24 08:20:00-04:00,PRAH,negative
1030472.0,Shares of several healthcare companies are trading lower amid market volatility. Sunday's fiscal stimulus bill failed a procedural senate vote while the Fed Monday morning announced further stimulus measures to support liquidity.,2020-03-23 11:31:00-04:00,PRAH,negative
1030473.0,"Jefferies Maintains Buy on PRA Health Sciences, Lowers Price Target to $89",2020-03-23 09:26:00-04:00,PRAH,negative
1030474.0,"The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company",2020-03-20 07:44:00-04:00,PRAH,negative
1030475.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-19 10:49:00-04:00,PRAH,negative
1030476.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,PRAH,positive
1030477.0,"SunTrust Robinson Humphrey Maintains Buy on PRA Health Sciences, Lowers Price Target to $89",2020-03-17 12:14:00-04:00,PRAH,negative
1030478.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,PRAH,neutral
1030479.0,Stocks That Hit 52-Week Lows On Friday,2020-03-13 11:13:00-04:00,PRAH,negative
1030480.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,PRAH,negative
1030481.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,PRAH,negative
1030482.0,"Baird Maintains Outperform on PRA Health Sciences, Raises Price Target to $128",2020-02-21 08:37:00-05:00,PRAH,neutral
1030483.0,"PRA Health Sciences Sees Q1 EPS $1.05-$1.15 Vs $1.29 Estimate, Sales $765M-$787M Vs $789.18M Estimate; FY20 EPS $5.77-$5.97 Vs $5.1 Estimate, Sales $3.23B-$3.36B Vs $.2.21B Estimate",2020-02-20 16:07:00-05:00,PRAH,neutral
1030484.0,"PRA Health Sciences Q4 EPS $1.54 Beats $1.47 Estimate, Sales $800.24M Beat $795.56M Estimate",2020-02-20 16:04:00-05:00,PRAH,neutral
1030485.0,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study",2020-02-20 07:06:00-05:00,PRAH,negative
1030486.0,"Earnings Scheduled For February 20, 2020",2020-02-20 04:17:00-05:00,PRAH,neutral
1030487.0,"The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions",2020-02-16 15:03:00-05:00,PRAH,positive
1030488.0,"Citigroup Initiates Coverage On PRA Health Sciences with Neutral Rating, Announces $120 Price Target",2020-01-07 07:18:00-05:00,PRAH,neutral
1030489.0,Wolfe Research Upgrades PRA Health Sciences to Outperform,2019-11-14 11:21:00-05:00,PRAH,neutral
1030490.0,PRA Health Raises FY19 Adj. EPS Guidance From $4.93-$5.08 To $5.07-$5.12 vs $5.07 Est.,2019-10-30 17:14:00-04:00,PRAH,neutral
1030491.0,PRA Health Sciences Reaffirms FY19 Sales Guidance $3.02B-$3.10B vs $3.06B Est.,2019-10-30 17:11:00-04:00,PRAH,neutral
1030492.0,"PRA Health Sciences Q3 EPS $1.32 Beats $1.29 Estimate, Sales $780.7M Beat $771.3M Estimate",2019-10-30 17:09:00-04:00,PRAH,neutral
1030493.0,"UPDATE: KeyBanc On PRA Health Sciences Also Notes 'By our models, PRAH should be able to generate revenue growth of 8%+ and EBITDA growth of 12%+ in 2020 even in the face of some integration headwinds at Symphony Health'",2019-09-13 11:40:00-04:00,PRAH,positive
1030494.0,"UPDATE: KeyBanc Maintains Overweight On PRA Health Sciences, Announces $118 'after follow-up conversations with management and with the stock trading at a sizable discount'",2019-09-13 11:40:00-04:00,PRAH,negative
1030495.0,"Benzinga's Top Upgrades, Downgrades For September 13, 2019",2019-09-13 09:56:00-04:00,PRAH,positive
1030496.0,"KeyBanc Upgrades PRA Health Sciences to Overweight, Announces $118 Price Target",2019-09-13 05:52:00-04:00,PRAH,negative
1030497.0,"Barclays Maintains Overweight on PRA Health Sciences, Raises Price Target to $118",2019-09-04 12:18:00-04:00,PRAH,negative
1030498.0,PRA Health Sciences Prices Secondary Offering of 6.6M Shares @$97.50/Share,2019-09-04 06:05:00-04:00,PRAH,positive
1030499.0,PRA Health Sciences Announces $500M Share Repurchase Program,2019-09-03 18:01:00-04:00,PRAH,positive
1030500.0,PRA Health Sciences Announces Strategic Alliance Between Symphony Health And Close-Up International,2019-08-19 10:20:00-04:00,PRAH,neutral
1030501.0,"Shares of diagnostics and research companies are trading higher in sympathy with Syneos Health, which reported strong Q2 results and raised FY19 guidance.",2019-08-06 13:54:00-04:00,PRAH,positive
1030502.0,PRA Health Sciences shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.,2019-07-31 16:26:00-04:00,PRAH,positive
1030503.0,"PRA Health Sciences Q2 EPS $1.22 Beats $1.18 Estimate, Sales $763.3M Beat $762.73M Estimate",2019-07-31 16:24:00-04:00,PRAH,neutral
1030504.0,Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.,2019-06-04 13:07:00-04:00,PRAH,positive
1030505.0,"KeyBanc Downgrades PRA Health Sciences, Inc. - Common Stock to Sector Weight",2019-05-03 06:12:00-04:00,PRAH,neutral
1030506.0,"PRA Health Sciences Reaffirms FY19 Revenue Guidance Of $3.09-3.2 Bln Vs. $3.14 Bln Estimate, Reaffirms FY19 Adj. EPS Guidance Of $4.93-5.08/Share Vs. $5.02 Estimate",2019-05-01 16:07:00-04:00,PRAH,neutral
1030507.0,"PRA Health Sciences, Inc. - Common Stock Q1 EPS $1.1 Beats $1.06 Estimate, Sales $722 M Miss $732.26M Estimate",2019-05-01 16:05:00-04:00,PRAH,negative
1030508.0,"The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue",2019-05-01 07:39:00-04:00,PRAH,neutral
1030509.0,"PRA Health Sciences Filing Shows Registration For Common Stock Offering Via Selling Shareholders, No Size Disclosed",2019-03-06 17:06:00-05:00,PRAH,negative
1030510.0,"Baird Maintains Outperform on PRA Health Sciences, Raises Price Target to $122",2019-02-28 08:42:00-05:00,PRAH,neutral
1030511.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,PRAH,positive
1030512.0,"PRA Health Sciences, Inc. - Common Stock Q4 Adj. EPS $1.31 Beats $1.27 Estimate, Sales $729.6M Miss $741.59M Estimate",2019-02-27 17:29:00-05:00,PRAH,negative
1030513.0,"Earnings Scheduled For February 27, 2019",2019-02-27 04:03:00-05:00,PRAH,neutral
1030514.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,PRAH,neutral
1030515.0,"Jim Cramer Shares His Thoughts On JPMorgan, PRA Health Sciences And Funko",2018-12-07 07:38:00-05:00,PRAH,positive
1030516.0,"Stocks Which Set New 52-Week High Yesterday, Mon., Dec. 3, 2018",2018-12-04 09:20:00-05:00,PRAH,neutral
1030517.0,"Stocks Which Set New 52-Week High Yesterday, Thurs., Nov. 29, 2018",2018-11-30 10:25:00-05:00,PRAH,neutral
1030518.0,"PRA Health Reaffirms FY18 Adj. EPS Guidance $4.22-$4.27 vs $4.19 Estimate, Sales $2.87B-$2.92B vs $2.91B Est.",2018-10-31 16:39:00-04:00,PRAH,neutral
1030519.0,"PRA Health Sciences, Inc. - Common Stock Q3 EPS $1.13 Beats $1.07 Estimate, Sales $717.596M Miss $726.88M Estimate",2018-10-31 16:39:00-04:00,PRAH,negative
1030520.0,"Stocks Which Set New 52-Week High Friday, September 14th",2018-09-17 09:28:00-04:00,PRAH,neutral
1030521.0,"Stocks Which Set New 52-Week High Yesterday, September 13th",2018-09-14 09:26:00-04:00,PRAH,neutral
1030522.0,"The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut",2018-09-14 08:38:00-04:00,PRAH,neutral
1030523.0,"Stocks Which Set New 52-Week High Yesterday, September 12",2018-09-13 09:44:00-04:00,PRAH,neutral
1030524.0,"The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx",2018-09-13 08:42:00-04:00,PRAH,neutral
1030525.0,"Stocks Which Set New 52-Week High Yesterday, September 11th",2018-09-12 12:17:00-04:00,PRAH,neutral
1030526.0,"The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet",2018-09-11 08:25:00-04:00,PRAH,negative
1030527.0,"Stocks Which Set New 52-Week High Yesterday, September 5th",2018-09-06 08:48:00-04:00,PRAH,neutral
1030528.0,PRA Health Sciences Secondary 6.5M Share Offering By KKR AAffiliate Priced At $101.50,2018-08-07 08:28:00-04:00,PRAH,positive
1030529.0,PRA Health Sciences Announces 6.5M Share Common Stock Secondary Offering,2018-08-06 16:59:00-04:00,PRAH,positive
1030530.0,"Barclays Maintains Overweight on PRA Health Sciences, Raises Price Target to $115",2018-08-02 09:51:00-04:00,PRAH,negative
1030531.0,"PRA Health Sciences Sees FY18 Adj. EPS $4.13-$4.23 vs $4.12 Est., Sales $2.87B-$2.92B vs $2.92B Est.",2018-08-01 16:02:00-04:00,PRAH,neutral
1030532.0,"PRA Health Sciences, Inc. Q2 Adj. EPS $1.00 Beats $0.96 Estimate, Sales $722.8M Beat $709.93M Estimate",2018-08-01 16:01:00-04:00,PRAH,neutral
1030533.0,"Stocks Which Set New 52-Week High Yesterday, July 26th:",2018-07-27 10:42:00-04:00,PRAH,neutral
1030534.0,"Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter",2018-07-27 08:44:00-04:00,PRAH,neutral
1030535.0,"Stocks Which Set New 52-Week High Yesterday, July 25th",2018-07-26 11:00:00-04:00,PRAH,neutral
1030536.0,"Stocks Which Set New 52-Week High Yesterday, July 24th:",2018-07-25 12:14:00-04:00,PRAH,neutral
1030537.0,Stocks Which Set New 52-Week Highs Friday,2018-07-23 11:08:00-04:00,PRAH,neutral
1030538.0,"Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering",2018-07-13 08:34:00-04:00,PRAH,neutral
1030539.0,PRA Health Sciences Promotes Michael Bonello to CFO As Linda Baddour Retires,2018-04-25 16:46:00-04:00,PRAH,positive
1030540.0,"PRA Health Reaffirms FY18 Sales $2.84B-$2.95B vs $2.91B Est., Adj. EPS $4.00-$4.15 vs $4.12 Est.",2018-04-25 16:20:00-04:00,PRAH,neutral
1030541.0,"PRA Health Q1 Adj. EPS $0.85 Beats $0.84 Est., Sales $701.84M Beats $694.84M Est.",2018-04-25 16:04:00-04:00,PRAH,neutral
1030542.0,Using Social Media To Accelerate Drug Development: 'The Only Way To Change The Paradigm',2018-04-02 16:40:00-04:00,PRAH,neutral
1030543.0,"Credit Suisse Maintains Outperform on PRA Health Sciences, Raises price target to $104.00",2018-02-22 09:13:00-05:00,PRAH,positive
1030544.0,"PRA Health Sciences Reports Q4 Adj. EPS $1.04 vs $1.03 Est., Sales $655.9M vs $472.4M Est.",2018-02-21 16:01:00-05:00,PRAH,neutral
1030545.0,"Earnings Scheduled For February 21, 2018",2018-02-21 04:00:00-05:00,PRAH,neutral
1030546.0,"Benzinga's Top Upgrades, Downgrades For January 24, 2018",2018-01-24 09:27:00-05:00,PRAH,positive
1030547.0,Mizuho Downgrades PRA Health Sciences to Neutral,2018-01-24 07:42:00-05:00,PRAH,neutral
1030548.0,"Mitsubishi UFJ Initiates Coverage On PRA Health Sciences with Overweight Rating, Announces $102.00 Price Target",2017-12-15 06:20:00-05:00,PRAH,negative
1030549.0,"Benzinga's Top Upgrades, Downgrades For December 11, 2017",2017-12-11 09:31:00-05:00,PRAH,positive
1030550.0,"Barclays Initiates Coverage On PRA Health Sciences with Overweight Rating, Announces $94.00 Price Target",2017-12-11 06:38:00-05:00,PRAH,negative
1030551.0,PRA Health Sciences Reaffirms FY 2017 Guidance,2017-10-25 16:19:00-04:00,PRAH,neutral
1030552.0,"PRA Health Sciences Q3 Adj. EPS $0.88 vs $0.85 Est., Sales $598.5M vs $484.3M Est.",2017-10-25 16:18:00-04:00,PRAH,neutral
1030553.0,"Mizuho Initiates Coverage On PRA Health Sciences with Buy Rating, Announces $82.00 Price Target",2017-09-21 06:16:00-04:00,PRAH,neutral
1030554.0,22 Biggest Mid-Day Losers For Wednesday,2017-08-09 13:00:00-04:00,PRAH,negative
1030555.0,18 Stocks Moving In Wednesday's Pre-Market Session,2017-08-09 08:19:00-04:00,PRAH,neutral
1030556.0,"PRA Health Sciences Prices 10M Share Secondary, Price Not Disclosed",2017-08-09 07:00:00-04:00,PRAH,positive
1030557.0,PRA Health Sciences Says Selling Stockholders are Offering 10M Shares of Co's Common Stock; PRA Won't Receive Any Proceeds from Sale -424B7,2017-08-09 06:11:00-04:00,PRAH,positive
1030558.0,PRA Health Sciences Reports Offering Of 10M Shares Of Common Stock,2017-08-08 16:48:00-04:00,PRAH,positive
1030559.0,"PRA Health Sciences Reports Q2 Adj. EPS $0.79 vs. $0.74 Est., Sales $533.7M May Not Compare To $447.79M Est.",2017-08-07 16:30:00-04:00,PRAH,neutral
1030560.0,"Earnings Scheduled For August 7, 2017",2017-08-07 05:03:00-04:00,PRAH,neutral
1030561.0,"Jefferies Highlights A Pair Trade In Pharma: Buy ICON, Hold Tight On INC Research",2017-06-29 14:46:00-04:00,PRAH,neutral
1030562.0,"Benzinga's Top Upgrades, Downgrades For June 26, 2017",2017-06-26 09:21:00-04:00,PRAH,positive
1030563.0,"Bank of America Initiates Coverage On PRA Health Sciences with Buy Rating, Announces $89.00 Price Target",2017-06-26 07:57:00-04:00,PRAH,neutral
1030564.0,PRA Health Sciences and Jumo Report Partnership For Pediatric Clinical Development,2017-06-19 10:00:00-04:00,PRAH,neutral
1030565.0,DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme,2017-05-11 08:33:00-04:00,PRAH,neutral
1030566.0,"PRA Health Sciences Adj. $0.62 vs $0.60 Est., Sales 4487.76M vs $419.5M Est.",2017-04-25 16:01:00-04:00,PRAH,neutral
1030567.0,"Benzinga's Top Upgrades, Downgrades For February 27, 2017",2017-02-27 09:38:00-05:00,PRAH,positive
1030568.0,Avondale Partners Upgrades PRA Health Sciences To Market Perform,2017-02-27 06:29:00-05:00,PRAH,neutral
1030569.0,"PRA Health Sciences Reports Q4 Adj. EPS $0.71 vs. $0.64 Est., Rev. $472M vs. $405M Est.",2017-02-22 16:01:00-05:00,PRAH,neutral
1030570.0,"Benzinga's Top Upgrades, Downgrades For February 6, 2017",2017-02-06 09:40:00-05:00,PRAH,positive
1030571.0,Credit Suisse Upgrades PRA Health Sciences To Outperform,2017-02-06 06:41:00-05:00,PRAH,positive
1030572.0,PRA Health Sciences Shares Gap Down on Volume,2016-11-29 14:53:00-05:00,PRAH,positive
1030573.0,"PRA Health Sciences, Inc. Announces Secondary Offering of 7,500,000 Shares of Common Stock",2016-11-10 16:36:00-05:00,PRAH,positive
1030574.0,"PRA Health Sees FY16 Rev. $1.568-$1.573B vs. Est. $1.57B, EPS $2.45-$2.48 vs. Est. $2.47",2016-11-02 16:25:00-04:00,PRAH,neutral
1030575.0,"PRA Health Sciences Reports Q3 EPS $0.64 vs. Est. $0.64, Rev. $399.8M vs. Est. $394.8M",2016-11-02 16:24:00-04:00,PRAH,neutral
1030576.0,UBS Downgrades PRA Health Sciences to Neutral,2016-09-06 05:32:00-04:00,PRAH,neutral
1030577.0,"PRA Health Sciences Reports Q2 EPS $0.63 vs. Est. $0.58, Rev. $394.2M vs. Est. $381.25M",2016-07-28 16:22:00-04:00,PRAH,neutral
1030578.0,Benzinga's Top Initiations,2016-06-21 09:21:00-04:00,PRAH,positive
1030579.0,PRA Health Shares Initiated Neutral By Credit Suisse,2016-06-21 08:52:00-04:00,PRAH,positive
1030580.0,First Analysis Initiates Coverage on PRA Health Sciences at Equal-weight,2016-06-21 07:52:00-04:00,PRAH,neutral
1030581.0,"Credit Suisse Initiates Coverage on PRA Health Sciences at Neutral, Announces $43.00 PT",2016-06-21 04:29:00-04:00,PRAH,positive
1030582.0,"KeyBanc Expecting PRA Health Sciences To Beat Estimates, Upgrades To Overweight",2016-06-13 12:22:00-04:00,PRAH,negative
1030583.0,Benzinga's Top Upgrades,2016-06-13 09:07:00-04:00,PRAH,positive
1030584.0,KeyBanc Upgrades PRA Health Sciences to Overweight,2016-06-13 06:56:00-04:00,PRAH,negative
1030585.0,"Citigroup Upgrades PRA Health Sciences to Buy, Raises PT to $53.00",2016-05-04 06:51:00-04:00,PRAH,neutral
1030586.0,12 Stocks Moving In Tuesday's Pre-Market Session,2016-05-03 08:25:00-04:00,PRAH,neutral
1030587.0,PRA Health Sciences Reports Offering of 5M Snares of Common Stock,2016-05-02 16:56:00-04:00,PRAH,neutral
1030588.0,UPDATE: PRA Health Raises FY16 Adj. EPS Outlook from $2.32-$2.42 to $2.41-$2.48 vs $2.38 Est.,2016-04-27 16:45:00-04:00,PRAH,neutral
1030589.0,"PRA Health Sciences Reports Q1 Adj. EPS $0.55 vs $0.53 Est., Sales $372.3M vs $372.2M Est.; Raises Outlook",2016-04-27 16:44:00-04:00,PRAH,neutral
1030590.0,PRA Health Sciences Reports Received Recognition from ViE,2016-03-31 09:02:00-04:00,PRAH,neutral
1030591.0,Benzinga's Top Upgrades,2016-03-28 09:06:00-04:00,PRAH,positive
1030592.0,"SunTrust Robinson Humphrey Upgrades PRA Health Sciences to Buy, Raises PT to $51.00",2016-03-28 07:44:00-04:00,PRAH,neutral
1030593.0,UPDATE: PRA Health Sciences Reports 5M  Share Secondary Offering,2016-03-02 16:45:00-05:00,PRAH,positive
1030594.0,PRA Health Sciences Files Stock Offering For Selling Shareholders,2016-03-02 16:27:00-05:00,PRAH,neutral
1030595.0,"PRA Health Sees FY16 Service Sales Growth 11-14%, Adj. EPS $2.32-$2.42 vs $2.19 Est.",2016-02-24 16:15:00-05:00,PRAH,positive
1030596.0,"PRA Health Reports Q4 Adj. EPS $0.59 vs $0.49 Est., Sales $362.3M vs $353M Est.",2016-02-24 16:15:00-05:00,PRAH,neutral
1030597.0,Stocks Hitting 52-Week Highs,2015-12-15 10:01:00-05:00,PRAH,neutral
1030598.0,"WuXi PharmaTech, PRA Health Sciences Restructure Relationship in China for Delivery of Clinical Trial Management Services",2015-12-07 19:22:00-05:00,PRAH,neutral
1030599.0,Benzinga's Top Initiations,2015-11-19 09:34:00-05:00,PRAH,positive
1030600.0,"SunTrust Robinson Humphrey Initiates Coverage on PRA Health Sciences at Neutral, Announces $47.00 PT",2015-11-19 06:43:00-05:00,PRAH,neutral
1030601.0,Avondale Partners Downgrades PRA Health Sciences to Underperform,2015-11-04 07:52:00-05:00,PRAH,neutral
1030602.0,PRA Health Sciences Raises FY15 EPS From $1.75-$1.85 To $1.89-$1.92/Share,2015-11-02 16:01:00-05:00,PRAH,neutral
1030603.0,"PRA Health Sciences Reports Q3 EPS $0.52 vs. Est. $0.45, Rev. $345.1M vs. Est. $346.05M",2015-11-02 16:01:00-05:00,PRAH,neutral
1030604.0,PRA Health Sciences Collaborates With AMR to Accelerate Vaccine Development,2015-09-29 10:01:00-04:00,PRAH,neutral
1030605.0,"Credit Suisse Assumes PRA Health Sciences at Outperform, Announces $47.00 PT",2015-08-14 04:48:00-04:00,PRAH,positive
1030606.0,"PRA Health Raises FY15 Adj. EPS Outlook from $1.62-$1.72 to $1.75-$1.85 vs $1.67 Est., Sales Affirmed in $1.34B-$1.39B Range",2015-07-27 17:10:00-04:00,PRAH,neutral
1030607.0,"PRA Health Sciences Reports Q2 Adj. EPS $0.47 vs $0.40 Est., Service Sales $336.5M vs $336.7M Est.",2015-07-27 17:08:00-04:00,PRAH,neutral
1030608.0,KeyBanc Initiates PRA Health Sciences With Sector Weight,2015-07-02 09:32:00-04:00,PRAH,neutral
1030609.0,Benzinga's Top Initiations,2015-07-02 09:24:00-04:00,PRAH,positive
1030610.0,KeyBanc Initiates Coverage on PRA Health Sciences at Sector Weight,2015-07-02 07:13:00-04:00,PRAH,neutral
1030611.0,PRA Continues the Transformation of Clinical Trials With Predictivv(TM),2015-06-15 10:00:00-04:00,PRAH,neutral
1030612.0,Jefferies Boosts Targets Across Pharmaceutical Service Stocks,2015-05-27 11:59:00-04:00,PRAH,positive
1030613.0,"PRA Health Sciences Reports Adj EPS $0.41 Vs Est $0.31, Sales $388.6M Vs Est $329.76M, Sees 2015 Adj EPS $1.62-$1.72",2015-05-06 17:12:00-04:00,PRAH,neutral
1030614.0,PRA Health Sciences Reports Q1 Adj. EPS $0.41 vs $0.31 Est.; Sees FY15 Adj. EPS $1.62-$1.72,2015-05-06 16:54:00-04:00,PRAH,neutral
1030615.0,Jefferies Previews Booming Biotech Earnings,2015-04-27 09:02:00-04:00,PRAH,neutral
1030616.0,PRA Health Expands Global Phase I Patient Strategy,2015-03-30 10:01:00-04:00,PRAH,positive
1030617.0,PRA Health Reports Q4 Adj. EPS $0.35 vs $0.30 Est.; Sees FY15 Adj. EPS $1.35-$1.45,2015-02-18 18:55:00-05:00,PRAH,neutral
1030618.0,William Blair Initiates Coverage on PRA Health Sciences at Outperform,2014-12-22 07:04:00-05:00,PRAH,neutral
1030619.0,Analyst Roundup On PRA Health Sciences After Quiet Period Ends,2014-12-08 11:57:00-05:00,PRAH,neutral
1030620.0,UPDATE: Citigroup Initiates Coverage On PRA Health Sciences On Ingredients For Success,2014-12-08 09:20:00-05:00,PRAH,positive
1030621.0,Benzinga's Top Initiations,2014-12-08 09:14:00-05:00,PRAH,positive
1030622.0,Jefferies Initiates PRA Health Sciences At Buy,2014-12-08 08:57:00-05:00,PRAH,neutral
1030623.0,"Credit Suisse Initiates Coverage on PRA Health Sciences at Outperform, Announces $27.00 PT",2014-12-08 08:53:00-05:00,PRAH,positive
1030624.0,"Citigroup Initiates Coverage on PRA Health Sciences at Neutral, Announces $24.00 PT",2014-12-08 08:49:00-05:00,PRAH,neutral
1030625.0,"UBS Initiates Coverage on PRA Health Sciences at Buy, Announces $28.00 PT",2014-12-08 06:51:00-05:00,PRAH,neutral
1030626.0,"Baird Initiates Coverage on PRA Health Sciences at Outperform, Announces $28.00 PT",2014-12-08 05:57:00-05:00,PRAH,neutral
1030627.0,"Jefferies Initiates Coverage on PRA Health Sciences at Buy, Announces $27.00 PT",2014-12-08 05:56:00-05:00,PRAH,neutral
1030628.0,"Shares of PRA Health Sciences Open for Trade at $18.55/Share, IPO Priced at $18",2014-11-13 11:08:00-05:00,PRAH,positive
1030629.0,Expected IPOs For November 13,2014-11-13 09:15:00-05:00,PRAH,neutral
1030630.0,PRA Health Sciences Expects 18.6M Share IPO to Price $20.00-$23.00/Share,2014-11-03 06:17:00-05:00,PRAH,positive
